Mika Kitahora

Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy

Kazuhiro Yoshida, Takao Takahashi, Y. Ueda, 2021, Journal of pharmaceutical health care and sciences.

Efficacy of Single-dose First-generation 5-HT3 Receptor Antagonist and Dexamethasone for Preventing Nausea and Vomiting Induced by Low-dose Carboplatin-based Chemotherapy.

S. Minatoguchi, Y. Ohno, Y. Itoh, 2017, Anticancer research.

Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy

Kazuhiro Yoshida, Takao Takahashi, Takuma Ishihara, 2020, Supportive Care in Cancer.

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

Kazuhiro Yoshida, Takao Takahashi, Takuma Ishihara, 2019, The oncologist.

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study

Kazuhiro Yoshida, Takao Takahashi, Takuma Ishihara, 2019, The oncologist.

Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.

Y. Ohno, T. Sugiyama, A. Suzuki, 2019, Lung cancer.

Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer

T. Hayashida, A. Suzuki, A. Nagayama, 2024, The oncologist.